Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 33Active not recruiting 12Not yet recruiting 7Completed 4Withdrawn 2Terminated 2Suspended 1

Sponsor Class

OTHER 3NIH 1

Study Type

Observational 2Interventional 2

Sponsor

Cancer Type

Thoracic 4Dermatologic 2Sarcoma 1Lymphoid 1Gastrointestinal 1

Conditions

Melanoma 6Lung Neoplasms 6Prostatic Neoplasms 5Breast Neoplasms 5Multiple Myeloma 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Ovarian Neoplasms 3Osteosarcoma 3Lymphoma, Non-Hodgkin 3Leukemia, Myeloid, Acute 3Barrett Esophagus 3Urinary Bladder Neoplasms 2Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Neuroblastoma 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Leukemia, Biphenotypic, Acute 2Gastroesophageal Reflux 2Central Nervous System Neoplasms 2Carcinoma, Renal Cell 2Brain Neoplasms 2Adenocarcinoma Of Esophagus 2Wilms Tumor 1Uveal Melanoma 1Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Urethral Neoplasms 1

Interventions

Carboplatin 341Paclitaxel 262Cisplatin 232Pemetrexed 226Docetaxel 206Erlotinib Hydrochloride 193Gemcitabine 178pembrolizumab 136Bevacizumab 121Radiotherapy 118Nivolumab 84Gefitinib 72Vinorelbine 64Cetuximab 58atezolizumab 47Afatinib 46durvalumab 44osimertinib 41Radiosurgery 35Ipilimumab 34Drug Therapy 32Taxes 30Albumin-Bound Paclitaxel 29130-nm albumin-bound paclitaxel 29Surgical Procedures, Operative 28Etoposide 25Irinotecan 24Sorafenib 21Cyclophosphamide 20Radiation 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Carcinoma, Non-Small-Cell Lung × Specimen Handling × Clear all
NCT03634241 2026-04-16

Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study

M.D. Anderson Cancer Center

Phase 2 Completed
45 enrolled 9 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04312308 2026-02-06

A Study for Identification of Predictive Immune Biomarker for Atezolizumab Therapy in NSCLC Patients

Yonsei University

Completed
100 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02595866 2024-08-09

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

National Cancer Institute (NCI)

Phase 1 Completed
58 enrolled 17 charts
DermatologicGastrointestinalLymphoidSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Recurrence, Sarcoma, Kaposi, HIV Infections

NCT05740501 2023-08-04

Pharmacokinetic Profiling of Pembrolizumab and Nivolumab in Patients With Melanoma and/or Non-Small Cell Lung Cancer

Mayo Clinic

Completed
13 enrolled
DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡